Literature DB >> 3109434

Mechanism of selective toxicity of 4-S-cysteinylphenol and 4-S-cysteaminylphenol to melanocytes.

S Ito, T Kato, K Ishikawa, T Kasuga, K Jimbow.   

Abstract

Our previous studies showed that 4-S-cysteinylphenol (4-S-CP) and 4-S-cysteaminylphenol (4-S-CAP) inhibit the growth of malignant melanoma and cause depigmentation of black skin. In this study we examined kinetic constants of CP and CAP as substrates for tyrosinases and their properties as sulphydryl scavengers. 4-S-CP and 4-S-CAP were found to be much better substrates for mushroom tyrosinase than L-tyrosine while their 2-S isomers were not the substrates. 4-S-CP and 4-S-CAP were also good substrates for mammalian tyrosinase. Upon tyrosinase oxidation the two phenols conjugated with cysteine to form the cysteinyl derivatives of the corresponding catechols via o-quinone forms. The tyrosinase oxidation product of 4-S-CP had a poor ability to conjugate with alcohol dehydrogenase, a sulphydryl enzyme, while that of 4-S-CAP had a much higher ability. These results suggest that in melanocytes these phenols are oxidised by tyrosinase to the corresponding o-quinone forms, some of which conjugate with sulphydryl enzymes through cysteine residues, thus exerting cytotoxic effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109434     DOI: 10.1016/0006-2952(87)90501-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  Immunomodulation of Melanoma by Chemo-Thermo-Immunotherapy Using Conjugates of Melanogenesis Substrate NPrCAP and Magnetite Nanoparticles: A Review.

Authors:  Yasuaki Tamura; Akira Ito; Kazumasa Wakamatsu; Takafumi Kamiya; Toshihiko Torigoe; Hiroyuki Honda; Toshiharu Yamashita; Hisashi Uhara; Shosuke Ito; Kowichi Jimbow
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

2.  In vivo antimelanoma effects of 4-S-cysteaminylphenol, a newly synthesized therapeutic agent specific to melanoma.

Authors:  M Kitagawa; T Nemoto; S Seki; S Ito; T Kasuga
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Tyrosine transport in a human melanoma cell line as a basis for selective transport of cytotoxic analogues.

Authors:  J M Pankovich; K Jimbow
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

4.  Thymidylate synthase as a target enzyme for the melanoma-specific toxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol.

Authors:  J A Prezioso; N Wang; W D Bloomer
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.

Authors:  Kowichi Jimbow; Yasue Ishii-Osai; Shosuke Ito; Yasuaki Tamura; Akira Ito; Akihiro Yoneta; Takafumi Kamiya; Toshiharu Yamashita; Hiroyuki Honda; Kazumasa Wakamatsu; Katsutoshi Murase; Satoshi Nohara; Eiichi Nakayama; Takeo Hasegawa; Itsuo Yamamoto; Takeshi Kobayashi
Journal:  J Skin Cancer       Date:  2013-02-21

6.  The killing effects of 4-S-cysteinylcatechol and analogues on human melanoma cells.

Authors:  I Yamada; S Seki; S Ito; O Matsubara; S Suzuki; T Kasuga
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

7.  The killing effect of 4-S-cysteaminylphenol, a newly synthesised melanin precursor, on B16 melanoma cell lines.

Authors:  I Yamada; S Seki; S Ito; S Suzuki; O Matsubara; T Kasuga
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.